Clear Street analyst Bill Maughan initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $190 price target Krystal’s first commercial product, Vyjuvek for the treatment of dystrophic epidermolysis bullosa, is now nearly two years into launch and the company is developing and marketing therapies from its herpes simplex virus-platform-derived pipeline of gene therapies, notes the analyst. The post Q1 pullback in the stock was “overdone” and current trading levels reflect “expectations below the likely range of possibilities for the foreseeable future,” says the analyst, who adds that Krystal has several pipeline programs that “would add to the valuation with any success.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Promising Pipeline and Strategic Expansions Drive Buy Rating
- Promising Developments in Krystal Biotech’s Gene Therapy Drive Buy Rating
- Krystal Biotech announces first patient dosed in Phase 3 trial of KB803
- Krystal Biotech’s Promising Growth and Strategic Initiatives Support Buy Rating
- Promising Clinical Data and Strategic Advancements Drive Buy Rating for Krystal Biotech